---

CEO, Likarda

Stella Vnook grew up in the former USSR, within the blast range of the Chernobyl nuclear disaster. She fled the bloc (via Poland, Austria, and Italy) to the US, spending the remainder of her youth in New York. Through hard work and inspiration, Vnook was determined to become something more than a refugee. 

Since joining Likarda, Vnook has focused on new avenues for its technology that will enable novel applications for cell and gene therapies, biologics, and traditional modalities. Likarda’s platform is based on Core Shell Spherification technology, which prevents therapeutic cells and molecules from degradation, preserving biologics without ultracold freezing and storage.

Watch our video interview with Stella Vnook

“Controversies shouldn't overshadow the potential benefits of cell therapy; they should underscore the importance of careful regulation, transparent communication, and ethical decision-making in advancing the field responsibly.”